

MEDICAL EXEMPTION TO COVID-19 VACCINATION GUIDANCE

Instructions for medical practitioners:

The purpose of this decision support tool is to assist medical practitioners in determining whether their patient meets the Australian Technical Advisory Group on Immunisation (ATAGI) listed reasons for a medical exemption to COVID-19 vaccination. Further information is outlined in the ATAGI clinical guidance https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/advice-for-providers/clinical-guidance.

This document can be used to assist with patient consultation, education and clinical decision making when assessing a person's eligibility for a medical exemption to COVID-19 vaccination. A patient must have medical contraindications to **all** of the COVID-19 vaccines available for use in Australia in order to be medically exempted from COVID-19 vaccination. If a patient has a medical contraindication to one brand of COVID-19 vaccine, they may be able to be offered an alternate brand, if suitable.

If your patient meets the below criteria for a medical contraindication to <u>one or more</u> COVID-19 vaccinations or a temporary exemption due to acute major medical illness, you should file this completed form in the patient's medical record and proceed with completing the **Australian Immunisation Registry (AIR) – immunisation medical exemption form (IM011)**. The IM011 form should then be returned to Services Australia, Australian Immunisation Register, for uploading to the patient's Immunisation Record. Following validation, a COVID-19 Medical Exemption Certificate will be issued if the patient has a medical contraindication to <u>all</u> COVID-19 vaccines available for use in Australia, or if temporary exemption criteria are met.

This form is not intended to be used as evidence of COVID-19 vaccination exemption.

Patient Details:		
Given Name:	Family Name:	
DOB: / / / /	Sex: Male Female	Prefer not to say
Medicare number	Patient reference number	
Residential address:		
E-mail address:	Phone No:	
Section A – Medical contraindication		
The patient must have a medication contraindication(s) to <u>all</u> COVID-19 vaccines available for use in Australia before a medical exemption to COVID-19 vaccination can be issued.		
Pfizer (Comirnaty) COVID-19 vaccine (TGA approved for ages 5+)	Moderna (Spikevax) COVID-19 vaccine (TGA approved for ages 6+)	Novavax Biocelect (Nuvaxovid) (TGA approved for ages 18+)
History of anaphylaxis to a component of the Pfizer (Comirnaty) COVID-19 vaccine	History of anaphylaxis to a component of the Moderna (Spikevax) COVID-19 vaccine	History of anaphylaxis to a component of the Novavax (Nuvaxovid) COVID-19 vaccine
Serious adverse event¹ attributed to a previous dose of the Pfizer (Comirnaty) COVID-19 vaccine, being:	Serious adverse event¹ attributed to a previous dose of the Moderna (Spikevax) COVID-19 vaccine, being:	Serious adverse event¹ attributed to a previous dose of the Novavax (Nuvaxovid) COVID-19 vaccine, being:
The following are <u>not</u> considered medical contraindications to COVID-19 vaccination:		
 Family history of any adverse events following immunisation (AEFI) Presence of a chronic underlying medical condition Minor, common or expected side effects to a previous vaccine Other types of alleriges e.g. to other vaccines, medication, food, latex, venom etc Requesting preference of COVID-19 vaccine brand OR wishing to avoid vaccine mandate without medical contraindication Pregnancy 		



MEDICAL EXEMPTION TO COVID-19 VACCINATION GUIDANCE

OR



MEDICAL EXEMPTION TO COVID-19 VACCINATION GUIDANCE

Notes:

- 1. An adverse event following immunisation (AEFI) is considered serious if it:
 - requires in-patient hospitalisation or prolongation of existing hospitalisation OR results in persistent or significant disability/incapacity; and
 - has been determined following review by, and/or on the opinion of, an experienced immunisation provider/medical specialist to be associated with a risk of recurrence of the serious adverse event if another dose is given; and
 - has been reported to a state/territory adverse event surveillance system and/or the Therapeutic Goods Administration (TGA)

In Victoria, serious AEFI should be reported to SAEFVIC https://mvec.mcri.edu.au/saefvic/, the Victorian vaccine safety service.

- 2. Suitability for mRNA COVID-19 vaccines may be affected by inflammatory cardiac illness which requires consultation from an appropriate healthcare professional. Cardiac inflammation may include myocarditis, pericarditis, acute rheumatic fever, or acute rheumatic heart disease (i.e. with active myocardial inflammation). Further information is outlined in the ATAGI clinical guidance. https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/advice-for-providers/clinical-guidance.
- 3. Past confirmed infection with SARS-CoV-2 is not a contraindication to vaccination. ATAGI recommends that vaccination should be deferred in those with PCR confirmed SARS-CoV-2 infection until complete recovery from the acute illness. It is now recommended that all people should wait 6 months after confirmed SARS-CoV-2 before they receive their next COVID-19 vaccine dose. The next scheduled dose should then be given as soon as possible after this period.
- 4. People who have received an anti-SARS-CoV-2 monoclonal antibody or convalescent plasma should defer future doses of COVID-19 vaccine for at least 90 days. Chronic symptoms following COVID-19 ("long COVID") is not a contraindication to COVID-19 vaccines but does warrant a clinical discussion with the patient. Similarly, if a person is infected with SARS-CoV-2, the next dose should be deferred for 6 months after confirmed infection and should then be given as soon as possible after this period. In these situations, the person should consult their healthcare professional, and their individual circumstances should be considered. If vaccination is deferred, this can be indicated by completing section B of this form.